[go: up one dir, main page]

FR24C1006I2 - Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale - Google Patents

Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale

Info

Publication number
FR24C1006I2
FR24C1006I2 FR24C1006C FR24C1006C FR24C1006I2 FR 24C1006 I2 FR24C1006 I2 FR 24C1006I2 FR 24C1006 C FR24C1006 C FR 24C1006C FR 24C1006 C FR24C1006 C FR 24C1006C FR 24C1006 I2 FR24C1006 I2 FR 24C1006I2
Authority
FR
France
Prior art keywords
compounds
medical imaging
metal complexes
short
aminoalcohol chains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1006C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet SA filed Critical Guerbet SA
Publication of FR24C1006I1 publication Critical patent/FR24C1006I1/fr
Application granted granted Critical
Publication of FR24C1006I2 publication Critical patent/FR24C1006I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR24C1006C 2005-10-07 2024-02-19 Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale Active FR24C1006I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0510289A FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US73475605P 2005-11-09 2005-11-09
PCT/EP2006/067214 WO2007042506A1 (fr) 2005-10-07 2006-10-09 Composés comprenant des chaînes aminoalcool courtes et des complexes métalliques en imagerie médicale

Publications (2)

Publication Number Publication Date
FR24C1006I1 FR24C1006I1 (fr) 2024-04-19
FR24C1006I2 true FR24C1006I2 (fr) 2025-02-07

Family

ID=36636179

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0510289A Expired - Lifetime FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR24C1006C Active FR24C1006I2 (fr) 2005-10-07 2024-02-19 Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0510289A Expired - Lifetime FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Country Status (15)

Country Link
US (1) US8114863B2 (fr)
EP (2) EP2457914B1 (fr)
JP (2) JP5317270B2 (fr)
KR (2) KR20080080495A (fr)
CN (2) CN101305006B (fr)
BR (1) BRPI0617151B8 (fr)
CA (1) CA2625207C (fr)
DK (1) DK1931673T3 (fr)
ES (2) ES2519369T3 (fr)
FI (1) FIC20240003I1 (fr)
FR (2) FR2891830B1 (fr)
NL (1) NL301259I2 (fr)
PL (1) PL1931673T3 (fr)
PT (1) PT1931673E (fr)
WO (1) WO2007042506A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
US20110077396A1 (en) * 2009-09-30 2011-03-31 General Electric Company Intermediates for hydroxylated contrast enhancement agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
EP2766364B1 (fr) * 2011-08-17 2024-07-31 Merck & Cie Conjugués de folate d'entités de liaison d'albumine
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
HRP20170874T4 (hr) * 2013-04-26 2022-09-02 Guerbet Formulacija kontrastnog medija i odgovarajući postupak dobivanja
CN103467504B (zh) * 2013-09-23 2015-06-24 武汉工程大学 18f-氟标记卟啉-异氮杂茚自由基配合物及合成方法
CN104485193B (zh) * 2014-12-29 2016-11-02 广西师范大学 一种以酰腙类希夫碱为配体构筑的磁性材料及其制备方法
EP3101012A1 (fr) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
AU2016368545C1 (en) * 2015-12-10 2021-01-07 Bracco Imaging Spa Dimeric contrast agents
EP3223181B1 (fr) 2016-03-24 2019-12-18 Sofradim Production Système et procédé de génération d'un modèle et de simulation d'un effet sur un site de réparation chirurgicale
JP6909234B2 (ja) * 2016-04-13 2021-07-28 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． 造影剤
GB201610738D0 (en) * 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
WO2018096082A1 (fr) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft Composés de chélate de gadolinium à relaxivité élevée pour utilisation dans l'imagerie par résonance magnétique
KR102550339B1 (ko) * 2016-12-21 2023-07-04 지이 헬스케어 에이에스 Mri 영상화제로서 적합한 테트라아자비시클로-매크로사이클 기재의 망가니즈 킬레이트 화합물
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
WO2019122255A1 (fr) 2017-12-20 2019-06-27 General Electric Company Composés de chélates anioniques
KR102815156B1 (ko) 2018-08-06 2025-05-30 브라코 이미징 에스.피.에이. 가돌리늄 함유 pcta-기반 조영제
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
AU2019382881B2 (en) 2018-11-23 2025-06-12 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
PT4143153T (pt) * 2020-07-16 2023-12-19 Guerbet Sa Método para sintetizar diésteres de ácido 2-bromoglutárico
KR20230041007A (ko) 2020-07-17 2023-03-23 게르브 Pcta로부터 유도된 킬레이팅 리간드의 제조 방법
CN114105983B (zh) * 2021-11-09 2023-08-11 国科温州研究院(温州生物材料与工程研究所) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
EP4582432A4 (fr) * 2022-09-01 2025-12-10 Theranocure Co Ltd Nouveau composé et agent de contraste irm le comprenant
KR102845061B1 (ko) * 2022-09-01 2025-08-13 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
WO2024215535A2 (fr) * 2023-04-03 2024-10-17 Molecular Theranostics, Llc Peptides ciblant la fibronectine extra-domaine b et dérivés pour l'imagerie et la thérapie du cancer
EP4464708A1 (fr) 2023-05-17 2024-11-20 Bayer Aktiengesellschaft Nouveaux agents de contraste pour l'imagerie diagnostique
TW202510874A (zh) * 2023-09-01 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種大環化合物及其用途
CN118834263B (zh) * 2024-09-14 2024-12-03 成都施贝康生物医药科技有限公司 含短氨基醇链的化合物及其金属络合物和应用
CN118791488B (zh) * 2024-09-14 2024-11-15 成都施贝康生物医药科技有限公司 化合物、螯合物及其在磁共振成像中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135748A (en) 1960-05-27 1964-06-02 Little Inc A Heterocyclic substituted carbodhmides and method of preparation
DE3825040A1 (de) * 1988-07-20 1990-01-25 Schering Ag, 13353 Berlin 5- oder 6-ring- enthaltende makrocyclische polyaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4001655A1 (de) * 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5554748A (en) 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
ATE192047T1 (de) 1991-12-10 2000-05-15 Dow Chemical Co Bicylclische, polyazamakrocyclocarbonsäure- komplexe, konjugate, herstellung und verwendung als kontraststoffe
DK0661279T3 (da) * 1993-12-30 2001-07-16 Guerbet Sa Polyaminiserede ligander, metalkomplekser, fremgangsmåde til deres fremstilling og diagnostiske og terapeutiske anvendelser
EP0971747B1 (fr) * 1996-10-28 2005-12-28 Amersham Health AS Agents de contraste
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
FR2793795B1 (fr) * 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) * 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
AU768859B2 (en) 1999-07-29 2004-01-08 Dyax Corp. Binding moieties for fibrin
WO2001052900A2 (fr) * 2000-01-21 2001-07-26 Mallinckrodt Inc. Nouveaux chelateurs d'acides amines a protection orthogonale pour des applications biomedicales
US6450956B1 (en) 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
ITMI20011518A1 (it) * 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
FR2836916B1 (fr) * 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
CN1795015A (zh) 2003-05-23 2006-06-28 埃匹克斯医药品股份有限公司 螯合配位体和造影剂的光学纯和光学富集异构体
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
CA2526556C (fr) 2003-07-24 2012-09-25 Bracco Imaging S.P.A. Compositions radiopharmaceutiques stables et methodes pour leur preparation
US20050136003A1 (en) 2003-10-31 2005-06-23 Casebier David S. Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use
GB0326546D0 (en) 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
JP2007512321A (ja) 2003-11-24 2007-05-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
JP2007516288A (ja) 2003-12-23 2007-06-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 金属キレート剤として有用な新規化合物
US7988950B2 (en) * 2004-07-02 2011-08-02 Bracco Imaging S.P.A. Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (MRI) which contain a chelating moiety with polyhydroxylated substituents
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Also Published As

Publication number Publication date
CA2625207A1 (fr) 2007-04-19
FIC20240003I1 (fi) 2024-02-26
KR101440761B1 (ko) 2014-09-17
BRPI0617151A2 (pt) 2011-07-12
KR20140060565A (ko) 2014-05-20
FR2891830A1 (fr) 2007-04-13
DK1931673T3 (da) 2012-10-08
FR2891830B1 (fr) 2011-06-24
CN101305006A (zh) 2008-11-12
EP1931673A1 (fr) 2008-06-18
CA2625207C (fr) 2014-05-13
ES2390092T3 (es) 2012-11-06
JP2013209400A (ja) 2013-10-10
BRPI0617151B8 (pt) 2021-07-27
KR20080080495A (ko) 2008-09-04
NL301259I2 (nl) 2024-03-25
CN103224495A (zh) 2013-07-31
PT1931673E (pt) 2012-09-24
FR24C1006I1 (fr) 2024-04-19
EP1931673B1 (fr) 2012-08-29
CN101305006B (zh) 2013-04-24
JP5317270B2 (ja) 2013-10-16
JP2009513574A (ja) 2009-04-02
US20090169479A1 (en) 2009-07-02
BRPI0617151B1 (pt) 2020-08-11
JP5731572B2 (ja) 2015-06-10
CN103224495B (zh) 2015-07-15
WO2007042506A1 (fr) 2007-04-19
US8114863B2 (en) 2012-02-14
ES2519369T3 (es) 2014-11-06
EP2457914B1 (fr) 2014-08-06
PL1931673T3 (pl) 2012-11-30
EP2457914A1 (fr) 2012-05-30

Similar Documents

Publication Publication Date Title
FR24C1006I2 (fr) Composes comprenant des chaines aminoalcool courtes et des complexes metalliques en imagerie medicale
PL1863387T3 (pl) Nieinwazyjne pomiary w ludzkim ciele
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
IL178879A0 (en) Lipids, lipid complexes and use thereof
EP1804661A4 (fr) Diagnostic et systeme integres de traitement de maladies
EP1885248A4 (fr) Diagnostic ultrasons et appareil de traitement
EP1786311A4 (fr) Fonction d'etalement ponctuel volumetrique destinee au diagnostic et au traitement de l'oeil
IL188854A0 (en) Benzylpiperazine derivates and their medical use
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
EP1874800A4 (fr) Agents diagnostiques et thérapeutiques
IL185586A0 (en) 1,2,4-triazine derivatives, preparation and use thereof in human therapy
GB0516069D0 (en) Pharmaceutical and use thereof
GB0515758D0 (en) Improvements in and relating to optical coherence tomography
PL1896400T3 (pl) ALKILOTIOFENYLOGUANIDYNY ZNAKOWANE <sup>18</sup>F LUB <sup>11</sup>C DO STOSOWANIA W MEDYCZNYM OBRAZOWANIU
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
SI1786431T1 (sl) Izboljšane formulacije fotosenzibilizatorjev in njihova uporaba
RU2005119153A (ru) Средство лечения острой лучевой болезни
EP1951914A4 (fr) Méthodes et agents diagnostiques et thérapeutiques
GB0512726D0 (en) Multiple sclerosis therapy and diagnosis
ITBO20050746A1 (it) Procedimento di preparazione di un alimento ed alimento cosi' ottenuto
ZA200800396B (en) Benzylpiperazine derivates and their medical use
GB0505383D0 (en) Diagnosis and treatment
Cocchi et al. Allostatic working memory processing in schizophrenia: Human and animal model coherence
IL229981A0 (en) Use of fatty conjugates to treat diseases